FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385443485> ?p ?o ?g. }

• W4385443485 endingPage "935" @default.
• W4385443485 startingPage "925" @default.
• W4385443485 abstract "Background FGFR alterations are reported across various malignancies and might act as oncogenic drivers in multiple histologies. Erdafitinib is an oral, selective pan-FGFR tyrosine kinase inhibitor with activity in FGFR-altered advanced urothelial carcinoma. We aimed to evaluate the safety and activity of erdafitinib in previously treated patients with FGFR-altered advanced solid tumours. Methods The single-arm, phase 2 RAGNAR study was conducted at 156 investigative centres (hospitals or oncology practices that are qualified oncology study centres) across 15 countries. The study consisted of four cohorts based on tumour histology and patient age; the results reported in this Article are for the primary cohort of the study, defined as the Broad Panel Cohort, which was histology-agnostic. We recruited patients aged 12 years or older with advanced or metastatic tumours of any histology (except urothelial cancer) with predefined FGFR1–4 alterations (mutations or fusions according to local or central testing). Eligible patients had disease progression on at least one previous line of systemic therapy and no alternative standard therapy available to them, and an Eastern Cooperative Oncology Group performance status of 0–1 (or equivalent for adolescents aged 12–17 years). Patients received once-daily oral erdafitinib (8 mg/day with provision for pharmacodynamically guided up-titration to 9 mg/day) on a continuous 21-day cycle until disease progression or intolerable toxicity. The primary endpoint was objective response rate by independent review committee according to Response Evaluation Criteria In Solid Tumors (RECIST), version 1.1, or Response Assessment In Neuro-Oncology (RANO). The primary analysis was conducted on the treated population of the Broad Panel Cohort. This ongoing study is registered with ClinicalTrials.gov, number NCT04083976. Findings Patients were recruited between Dec 5, 2019, and Feb 15, 2022. Of 217 patients treated with erdafitinib, 97 (45%) patients were female and 120 (55%) were male. The data cutoff was Aug 15, 2022. At a median follow-up of 17·9 months (IQR 13·6–23·9), an objective response was observed in 64 (30% [95% CI 24–36]) of 217 patients across 16 distinct tumour types. The most common grade 3 or higher treatment-emergent adverse events related to erdafitinib were stomatitis (25 [12%]), palmar-plantar erythrodysaesthesia syndrome (12 [6%]), and hyperphosphataemia (11 [5%]). The most commonly occurring serious treatment-related adverse events (grade 3 or higher) were stomatitis in four (2%) patients and diarrhoea in two (1%). There were no treatment-related deaths. Interpretation RAGNAR results show clinical benefit for erdafitinib in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations who have exhausted other treatment options. These results support the continued development of FGFR inhibitors in patients with advanced solid tumours. Funding Janssen Research & Development." @default.
• W4385443485 created "2023-08-02" @default.
• W4385443485 creator A5000376876 @default.
• W4385443485 creator A5001115937 @default.
• W4385443485 creator A5003485856 @default.
• W4385443485 creator A5003912604 @default.
• W4385443485 creator A5004557221 @default.
• W4385443485 creator A5006299989 @default.
• W4385443485 creator A5006620245 @default.
• W4385443485 creator A5007178706 @default.
• W4385443485 creator A5008152833 @default.
• W4385443485 creator A5008217338 @default.
• W4385443485 creator A5011148364 @default.
• W4385443485 creator A5011207841 @default.
• W4385443485 creator A5011235559 @default.
• W4385443485 creator A5012667192 @default.
• W4385443485 creator A5013422468 @default.
• W4385443485 creator A5015509025 @default.
• W4385443485 creator A5016940852 @default.
• W4385443485 creator A5017258278 @default.
• W4385443485 creator A5017416578 @default.
• W4385443485 creator A5018054038 @default.
• W4385443485 creator A5018929039 @default.
• W4385443485 creator A5019197153 @default.
• W4385443485 creator A5020672869 @default.
• W4385443485 creator A5021572863 @default.
• W4385443485 creator A5022339242 @default.
• W4385443485 creator A5022533478 @default.
• W4385443485 creator A5023124061 @default.
• W4385443485 creator A5023848359 @default.
• W4385443485 creator A5023854119 @default.
• W4385443485 creator A5024410220 @default.
• W4385443485 creator A5025129613 @default.
• W4385443485 creator A5025272654 @default.
• W4385443485 creator A5025424120 @default.
• W4385443485 creator A5026022049 @default.
• W4385443485 creator A5026090288 @default.
• W4385443485 creator A5026459010 @default.
• W4385443485 creator A5026975414 @default.
• W4385443485 creator A5027991868 @default.
• W4385443485 creator A5028950420 @default.
• W4385443485 creator A5029848730 @default.
• W4385443485 creator A5030170547 @default.
• W4385443485 creator A5030260555 @default.
• W4385443485 creator A5032020875 @default.
• W4385443485 creator A5032809504 @default.
• W4385443485 creator A5032920234 @default.
• W4385443485 creator A5034739279 @default.
• W4385443485 creator A5036014337 @default.
• W4385443485 creator A5036507802 @default.
• W4385443485 creator A5036777070 @default.
• W4385443485 creator A5038570955 @default.
• W4385443485 creator A5040832651 @default.
• W4385443485 creator A5041593880 @default.
• W4385443485 creator A5041689810 @default.
• W4385443485 creator A5042202815 @default.
• W4385443485 creator A5042427780 @default.
• W4385443485 creator A5042656880 @default.
• W4385443485 creator A5043177546 @default.
• W4385443485 creator A5043348199 @default.
• W4385443485 creator A5044325012 @default.
• W4385443485 creator A5044831522 @default.
• W4385443485 creator A5045172802 @default.
• W4385443485 creator A5048037806 @default.
• W4385443485 creator A5048419838 @default.
• W4385443485 creator A5048728798 @default.
• W4385443485 creator A5048938240 @default.
• W4385443485 creator A5048945283 @default.
• W4385443485 creator A5049071296 @default.
• W4385443485 creator A5050628137 @default.
• W4385443485 creator A5050690834 @default.
• W4385443485 creator A5050715724 @default.
• W4385443485 creator A5052211893 @default.
• W4385443485 creator A5052248512 @default.
• W4385443485 creator A5052765751 @default.
• W4385443485 creator A5052808201 @default.
• W4385443485 creator A5053209984 @default.
• W4385443485 creator A5053719602 @default.
• W4385443485 creator A5053835464 @default.
• W4385443485 creator A5056097561 @default.
• W4385443485 creator A5058246995 @default.
• W4385443485 creator A5058526313 @default.
• W4385443485 creator A5059167780 @default.
• W4385443485 creator A5059965175 @default.
• W4385443485 creator A5060151897 @default.
• W4385443485 creator A5060176567 @default.
• W4385443485 creator A5060197505 @default.
• W4385443485 creator A5060366426 @default.
• W4385443485 creator A5062468425 @default.
• W4385443485 creator A5063649167 @default.
• W4385443485 creator A5064203357 @default.
• W4385443485 creator A5064758793 @default.
• W4385443485 creator A5065316719 @default.
• W4385443485 creator A5069943067 @default.
• W4385443485 creator A5072278925 @default.
• W4385443485 creator A5073366739 @default.
• W4385443485 creator A5073547992 @default.
• W4385443485 creator A5073795960 @default.

• next